Drug Profile
DNA C - EuroVacc
Alternative Names: DNA-C; DNA-HIV-C; DNA-HIV-PT123 vaccine; HIV clade C DNA vaccine; HIV DNA vaccine - EuroVaccLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator EuroVacc Foundation; GENEART; University of Regensburg
- Developer Centre Hospitalier Universitaire Vaudois; EuroVacc Foundation; HIV Vaccine Trials Network; International AIDS Vaccine Initiative; IPPOX Foundation; Medical Research Council; MRC/UVRI Uganda Research Unit on AIDS; National Institute of Allergy and Infectious Diseases; Novartis
- Class AIDS vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, Prevention) in Uganda (IM, Injection)
- 08 Mar 2020 Efficacy and safety data from a phase I/IIa trial in HIV uninfected volunteers presented at the 27th Conference on Retroviruses and Opportunistic Infections (CROI-2020)
- 28 Jan 2020 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, Prevention) in South Africa (IM, Injection)